The adeno-associated virus-mediated HSV-TK/GCV suicide system: a potential strategy for the treatment of bladder carcinoma
Tóm tắt
Novel treatment strategies such as gene therapy are warranted in view of the failure of current treatment approaches to cure a high percentage of patients with advanced bladder cancers. The emergence of cancer gene therapy potentially offers a number of exciting treatments. The majority of approaches involve strategies to suppress the function of activated oncogenes to restore the expression of functional tumour suppressor genes or to initiate tumour self-destruction. One gene therapy approach against tumours that holds great promise is suicide gene therapy. Herpes simplex virus thymidine kinase (HSV-TK) phosphorylates ganciclovir (GCV), which in turn interacts with cellular DNA polymerase and interferes with DNA synthesis to cause death of rapidly dividing cells. The development of an effective delivery system is absolutely critical to the usefulness and safety of gene therapy. At present, the adeno-associated virus (AAV) vector has the most promising potential in view of its non-pathogenicity, wide tropisms and long-term transgene expression in vivo. Gene therapy studies using different serotypes of recombinant AAV (rAAV) as delivery vehicles have proved rAAVs to be an effective modality of cancer gene therapy. In the present study, we investigated the suppression effect of AAV-mediated HSV-TK/GCV system on the bladder cancer cells and in mice xenograft models of bladder cancer. Our data demonstrate that rAAV-HSV-TK system controlled tumour cell growth and achieves strong antitumour efficacy in vivo. These findings provide a foundation for the development of potential targeted clinical therapies for bladder cancer in humans.
Tài liệu tham khảo
Malkowicz SB. Intravesical therapy for superficial bladder cancer. Semin Urol Oncol. 2000;18:280–8.
Edelman MJ. New approaches to treatment of metastatic bladder cancer. Curr Oncol Rep. 2000;2:379–85.
Block T. Chemotherapy of bladder carcinoma. Current status and trends. Urologe A. 1994;33:557–67.
Witjes JA, Wullink M, Oosterhof GO, de Mulder P. Toxicity and results of MVAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy in advanced urothelial carcinoma. Eur Urol. 1997;31:414–9.
Freund CT, Tong XW, Rowley D, Engehausen D, Frolov A, Kieback DG, et al. Combination of adenovirus-mediated thymidine kinase gene therapy with cytotoxic chemotherapy in bladder cancer in vitro. Urol Oncol. 2003;21:197–205.
Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res. 2006;4:218–27.
Seth P. Vector-mediated cancer gene therapy: an overview. Cancer Biol Ther. 2005;4:512–7.
Li J, Li HM, Zhu L, Song WJ, Li R, Wang DS, Dou KF. The adenovirus-mediated linamarase/linamarin suicide system: a potential strategy for the treatment of hepatocellular carcinoma. Cancer Lett. 2010;289:217–27.
Sharma A, Tandon M, Bangari DS, Mittal SK. Adenoviral vector-based strategies for cancer therapy. Curr Drug Ther. 2009;4:117–38.
Park SY, Lee W, Lee J, Kim IS. Combination gene therapy using multidrug resistance (MDR1) gene shRNA and herpes simplex virus-thymidine kinase. Cancer Lett. 2008;261:205–14.
Fillat C, Carrio M, Cascante A, Sangro B. Suicide gene therapy mediated by the Herpes Simplex virus thymidine kinase gene/Ganciclovir system: fifteen years of application. Curr Gene Ther. 2003;3:13–26.
Mori K, Iwata J, Miyazaki M, Osada H, Tange Y, Yamamoto T, Aiko Y, Tamura M, Shiroishi T. Bystander killing effect of thymidine kinase gene-transduced adult bone marrow stromal cells with ganciclovir on malignant glioma cells. Neurol Med Chir (Tokyo). 2010;50:545–53.
Paíno T, Gangoso E, Medina JM, Tabernero A. Inhibition of ATP-sensitive potassium channels increases HSV-tk/GCV bystander effect in U373 human glioma cells by enhancing gap junctional intercellular communication. Neuropharmacology. 2010;59:480–91.
Dachs GU, Hunt MA, Syddall S, Singleton DC, Patterson AV. Bystander or no bystander for gene directed enzyme prodrug therapy. Molecules. 2009;14:4517–45.
Zhang Y, Ma H, Zhang J, Liu S, Liu Y, Zheng D. AAV-mediated TRAIL gene expression driven by hTERT promoter suppressed human hepatocellular carcinoma growth in mice. Life Sci. 2008;82:1154–61.
Ma H, Liu Y, Liu S, Kung HF, Sun X, Zheng D, Xu R. Recombinant adenoassociated virus-mediated TRAIL gene therapy suppresses liver metastatic tumors. Int J Cancer. 2005;116:314–21.
Streck CJ, Dickson PV, Ng CY, Zhou J, Gray JT, Nathwani AC, Davidoff AM. Adeno-associated virus vector-mediated systemic delivery of IFN-beta combined with low-dose cyclophosphamide affects tumor regression in murine neuroblastoma models. Clin Cancer Res. 2005;11:6020–9.
Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J. 1991;10:3941–50.
El-Aneed A. An overview of current delivery systems in cancer gene therapy. J Control Release. 2004;94:1–14.
AAV Helper-Free System Instruction Manual. Revision A.02. http://www.stratagene.com.
Wu X, Dong X, Wu Z, Cao H, Niu D, Qu J, Wang H, Hou Y. A novel method for purification of recombinant adenoassociated virus vectors on a large scale. Chin Sci Bull. 2001;6:485–90.
Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector tool kit for human gene therapy. Mol Ther. 2006;14:316–27.
Pan J, Zhou X, Zeng G, Han R. Suppression of bladder cancer growth in mice by adeno-associated virus vector-mediated endostatin expression. Tumor Biol. 2011;32(2):301–10.
Xiao X, Li J, Samulski RJ. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associate virus vector. J Virol. 2009;70:8098–108.
Kyoko H, Lee J, Yoshie M, Naoki T, Hideo N, Toshimitsu H. The role of a HSV thymidine kinase stimulating substance, scopadulciol, in improving the efficacy of cancer gene therapy. J Gen Med. 2006;8:1056–67.
Mesnil M, Yamasaki H. Bystander effect in herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy: role of gap junctional intercellular communication. Cancer Res. 2000;60:3989–99.